Improved health - nicotine free |
|
Niccine® offers treatment against nicotine addiction with a high efficacy of antibodies and a long duration of the vaccination effect. |
Niccine® is given as an intramuscular
injection, and following vaccination, nicotine specific antibodies are
produced in the individual, which in turn binds to nicotine. This prevents
nicotine from reaching the brain and exerting its rewarding effects. The
nicotine molecule itself is too small to be recognized by the immune system.
Therefore, it is coupled to a carrier protein to form an immunoconjugate.
The immunoconjugate will elicit an immune response generating the nicotine
selective antibodies. By preventing the very occurrence of central nervous
system stimulations and the addictive pharmacological effects of nicotine,
secure protection is obtained. |
The carrier protein
The highly immunogenic carrier enables the large amount
of antibodies against nicotine after vaccination. With few immunizations
and low dosing needed, Niccine® will be convenient for patients. The
choice of the carrier protein is of major importance in order to achieve
a significant amount of antibodies against nicotine. Independent Pharmaceutica
has chosen a carrier protein which has an extensive clinical experience
and is known as a strong immunogen. It is thus approved for use as an
antigen and as a carrier protein in vaccines for children and adults.
Nicotine
hapten with precise action
The nicotine hapten was specially chosen to maximize
the selectivity of the generated antibodies. The choice was based on a
screening process of different nicotine haptens.
The unique combination of a strong immunogen and the precise action of the nicotine hapten aims at offering a secure and effective treatment against nicotine addiction. |